Move to ensure compliance with recent guidelines; discrepancies to attract severe action

The country's apex drug regulator plans periodic inspection of clinical trial sites to ensure these comply with the recently issued guidelines. If discrepancies are found, strict action is to be taken against the company and the trials might also be suspended, said a senior official in the the Drug Controller General of India (DCGI) office.